Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $38.32, for a total value of $766,400.00. Following the sale, the executive vice president owned 140,000 shares of the company’s stock, valued at approximately $5,364,800. The trade was a 12.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Up 0.5%

Royalty Pharma stock opened at $38.52 on Thursday. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $41.24. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The firm’s 50-day simple moving average is $38.26 and its 200 day simple moving average is $36.69. The stock has a market cap of $22.23 billion, a PE ratio of 29.15, a price-to-earnings-growth ratio of 2.02 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Friday, November 14th were issued a $0.22 dividend. The ex-dividend date of this dividend was Friday, November 14th. This represents a $0.88 annualized dividend and a yield of 2.3%. Royalty Pharma’s dividend payout ratio (DPR) is 66.67%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RPRX shares. The Goldman Sachs Group started coverage on Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective for the company. Morgan Stanley cut their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. TD Cowen upped their price target on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in shares of Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. USA Financial Formulas bought a new position in Royalty Pharma in the second quarter worth about $32,000. Financial Consulate Inc. purchased a new stake in Royalty Pharma in the third quarter worth about $35,000. Summit Securities Group LLC bought a new stake in Royalty Pharma during the 1st quarter valued at approximately $36,000. Finally, Larson Financial Group LLC raised its position in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.